NEUROCRINE BIOSCIENCES, INC.

(NBIX)
  Report
Delayed Nasdaq  -  04:00 2022-07-01 pm EDT
99.25 USD   +1.82%
06/15TRANSCRIPT : Neurocrine Biosciences, Inc. Presents at Goldman Sachs 43rd Annual Global Healthcare Conference, Jun-15-2022 10:40 AM
CI
06/13Neurocrine Biosciences Presents Data on Treatment of Adolescent Patients with Classic Congenital Adrenal Hyperplasia at ENDO 2022
PR
06/08Neurocrine Biosciences to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference
PR
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
06/27/2022 06/28/2022 06/29/2022 06/30/2022 07/01/2022 Date
99.93(c) 96.93(c) 98.46(c) 97.48(c) 99.25(c) Last
670 903 625 013 449 036 711 919 655 901 Volume
+1.72% -3.00% +1.58% -1.00% +1.82% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 1 380 M - -
Net income 2022 201 M - -
Net cash position 2022 1 010 M - -
P/E ratio 2022 48,8x
Yield 2022 -
Sales 2023 1 610 M - -
Net income 2023 322 M - -
Net cash position 2023 1 209 M - -
P/E ratio 2023 31,1x
Yield 2023 -
Capitalization 9 486 M 9 486 M -
EV / Sales 2022 6,14x
EV / Sales 2023 5,14x
Nbr of Employees 1 100
Free-Float 98,2%
More Financials
Company
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. The Company is focused on discovering, developing and marketing of pharmaceuticals for the treatment of neurological, endocrine and psychiatric-based diseases and disorders. Its portfolio includes treatments for tardive dyskinesia, Parkinson’s disease, endometriosis and uterine fibroids. Its product pipeline includes INGREZZA... 
More about the company
Ratings of Neurocrine Biosciences, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C-
More Ratings
All news about NEUROCRINE BIOSCIENCES, INC.
06/15TRANSCRIPT : Neurocrine Biosciences, Inc. Presents at Goldman Sachs 43rd Annual Global Hea..
CI
06/13Neurocrine Biosciences Presents Data on Treatment of Adolescent Patients with Classic C..
PR
06/08Neurocrine Biosciences to Present at the Goldman Sachs 43rd Annual Global Healthcare Co..
PR
06/06Jefferies Assumes Neurocrine Biosciences at Buy with $112 Price Target
MT
06/06Neurocrine Biosciences Honored at CARES Foundation 22nd Anniversary Gala
PR
06/06Neurocrine Biosciences Presents Data on Sleep Disturbances and OFF Time in Patients wit..
PR
06/06Neurocrine Biosciences, Inc. Presents Data on Sleep Disturbances and Off Time in Patien..
CI
06/03NEUROCRINE BIOSCIENCES : 2021 Annual Report*
PU
06/01NEUROCRINE BIOSCIENCES INC : Other Events (form 8-K)
AQ
05/25NEUROCRINE BIOSCIENCES : Announces Repurchase of Convertible Notes - Form 8-K
PU
05/25NEUROCRINE BIOSCIENCES INC : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
05/25Neurocrine Biosciences to Repurchase $179.4 Million of Convertible Notes
MT
05/24Neurocrine Biosciences Announces Repurchase of Convertible Notes
PR
05/23NEUROCRINE BIOSCIENCES INC : Change in Directors or Principal Officers, Submission of Matt..
AQ
05/13Neurocrine Biosciences Gets FDA's Orphan Drug Designation for Experimental Huntington D..
MT
More news
News in other languages on NEUROCRINE BIOSCIENCES, INC.
06/06Neurocrine Biosciences, Inc. présente des données sur les perturbations du sommeil et l..
05/04HISTORIQUE DES RÉACTIONS AUX BÉNÉFIC : Neurocrine Biosciences, indicateur de suivi de 33,3..
05/04NEUROCRINE BIOSCIENCES : baisse du BPA non GAAP au 1er trimestre, hausse du chiffre d'affa..
05/04Earnings Flash (NBIX) NEUROCRINE BIOSCIENCES affiche un chiffre d'affaires de 310,6 mil..
05/04Neurocrine Biosciences, Inc. annonce ses résultats pour le premier trimestre clos le 31..
More news
Analyst Recommendations on NEUROCRINE BIOSCIENCES, INC.
More recommendations
Chart NEUROCRINE BIOSCIENCES, INC.
Duration : Period :
Neurocrine Biosciences, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NEUROCRINE BIOSCIENCES, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Last Close Price 99,25 $
Average target price 113,75 $
Spread / Average Target 14,6%
EPS Revisions
Managers and Directors
Kevin Charles Gorman Executive Vice President & Chief Business Officer
Matthew C. Abernethy Chief Financial Officer
William H. Rastetter Chairman
Dimitri E. Grigoriadis Chief Research Officer
Bill Wilson Vice President-Information Technology & Operations
Sector and Competitors
1st jan.Capi. (M$)
NEUROCRINE BIOSCIENCES, INC.16.53%9 486
GILEAD SCIENCES, INC.-14.12%78 219
VERTEX PHARMACEUTICALS30.84%73 484
REGENERON PHARMACEUTICALS, INC.-5.72%64 152
WUXI APPTEC CO., LTD.-7.99%44 566
BIONTECH SE-38.91%38 276